16 November 2023 Thursday

Title Treatable Traits: a new horizon for airways diseases
Details Date: Thursday 16 November
Time: 12:30 – 13:30
Venue : Suntec Convention Center, Level 3 , Room 335-336
Synopsis To introduce the concepts and drive awareness of Treatable Traits in airways diseases. To discuss how the approach can be effectively implemented in clinical practice.
Objectives · To better understand the unmet need and introduce the treatable traits approach
· Provide insights on how to prioritize traits to aid implementation
· Improve understanding of endotypes and phenotypes in patients with COPD
· Give an overview of methods used for effective symptom and trait detection, with the potential to aid treatment
· Discuss the overlapping clinical features in COPD and asthma, and their significance on disease progression
Faculty Dr. Chris Compton, UK

Chris Compton leads various inhaled Respiratory teams in Global Medical Affairs, General Medicines TA, at GSK. He was previously Vice President and Senior Global Program Head and Clinical Sciences Head, Respiratory TA, at Novartis and Clinical Therapy Area Head for Allergy and Respiratory and Head of Translational Medicine, UK, at Pfizer. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine.

Chris is a physician with over 25 years of experience and has led various development programmes for respiratory new medicines development, including ICS/LABA, LAMA/LABA and triple therapy inhaled medicines and pre-competitive collaborations.
 Prof. Fernando Martinez, USA

Fernando Martinez is Chief of the Division of Pulmonary and Critical Care Medicine and Bruce Webster Professor of Medicine at Weill Cornell Medical College, New York-Presbyterian Hospital and Weill Cornell Medical Center in New York City, NY, USA. Professor Martinez’ professional memberships include the American Thoracic Society (ATS), the European Respiratory Society, and the American College of Chest Physicians. He was a member of the ATS and/or ERS committees that developed guidelines for the management of chronic obstructive pulmonary disease (COPD), interstitial lung diseases (ILD), respiratory infections, cardiopulmonary exercise testing, and research priorities in ILD and COPD. He is also a current member of the Global Initiative for Chronic Obstructive Lung Disease Science Committee.

In a career dedicated to pulmonary and critical medicine, Dr Martinez’s research interests have included the biological underpinnings and therapeutic approaches to COPD and ILDs, lung transplantation and lung volume reduction. He has authored over 600 publications, sits on numerous editorial boards, and presently serves as the Editor-in-Chief for the American Journal of Respiratory and Critical Care Medicine.
Prof. Paul Jones, UK

Paul Jones is Emeritus Professor of Respiratory Medicine at St George’s University of London. He was Head of the Division of Clinical Science at St George’s and a Global Medical Expert for GSK. His research now focusses on two areas – the effect of lung disease including COVID-19 on brain microstructure, and large chronic obstructive pulmonary disease (COPD) cohort studies in China and Japan.

Professor Jones developed the St George’s Respiratory Questionnaire and the COPD Assessment Test; he has also been involved in many clinical studies in COPD and was on the Science Committee and the Board of the Global Initiative for Chronic Obstructive Lung Disease. For the last 7 years he has been joint Chief Editor of the Clinical Respiratory Journal.
Schedule Time Description/Title
12:30 – 12:32 Welcome and Introduction Dr. Chris Compton
12:32 – 12:40 Turning tides in airways diseases: towards personalised medicine with Treatable Traits Dr. Chris Compton
12:40 –  13:00 Plain sailing: how can we keep Treatable Traits simple? Prof. Fernando Martinez
13:00 – 13:20 Recent insights from five scientific studies in COPD in China and Japan Sponsored by GSK Prof. Paul Jones
13:20 – 13:30 Q&A All, facilitated by Chris Compton

17 November 2023 Friday

Title Lung Cancer in Asia: Tailored Approaches to Screening & Management
Details Date: 17 Nov 2023
Time: 12:30 – 13:20
Venue: Suntec Convention Center, Level 4, Sentosa Hall 404A
Synopsis Asia has the highest burden of Lung Cancer. Studies have shown that a large proportion of Lung Cancer patients in Asia are never-smokers. In this talk, we will understand the specific Risk factors for Lung Cancer among Asian population as well as approaches to effectively identify them early.
Objectives – Discuss Asia LC Screening Consensus Recommendations- Risk Factors & approaches to Implement Lung Cancer Screening in Asia
– Discuss effective ways of Incidental Pulmonary Nodule (IPN) management in Asian population
Faculty SpeakerDr. David Lam
Chief of Respiratory Medicine Division
University of Hong Kong, Department of Medicine		 Dr. David Lam

Dr. David Lam is a respiratory physician with interest in translational research and clinical trials in respiratory diseases including lung cancer, smoking and airway physiology, COPD and interventional pulmonology. His research focuses on translational research with biomarkers in lung cancer and airway.

His lab has established & characterized lung cancer organoids representing local Chinese population and they are being used as cellular models for translational research on lung cancer, smoking and airway physiology research. Plasma EGFR mutations and circulating tumor markers are studied.

He also performs bronchoscopy including endobronchial ultrasonography and autofluorescence imaging. He is currently in the International Lung Screening Trial (ILST) Consortium, steering lung screening and relevant biomarker research.
ChairDr. Jansen Koh Meng Kwang
Head and Senior Consultant
Changi General Hospital, Respiratory and Critical Care Medicine		 Dr. Jansen Koh

Dr. Jansen Koh is currently assistant chairman, Medical Board (Performance Excellence) as well as chief for the Department of Respiratory & Critical Care Medicine at Changi General Hospital (CGH). His interest in respiratory & critical care is point of care ultrasonography, having obtained his certification from the American College of Chest Physicians.

In 2013, Dr Koh completed his fellowship in clinical simulation and medical education at the Learning Institute in Toronto, Canada. He is also a fellow at the Academy of Medicine Singapore, Royal College of Physicians Edinburgh and American College of Chest Physicians. He was the associate program director of the Internal Medicine Residency Program from 2012 to 2017 and is currently, the co-chair of the Changi Simulation Institute.
Schedule Time Description/Title
12:30 – 12:40 Opening & Introduction
– Singapore LC Landscape
– LC Screening Guidelines		 Dr. Jansen Koh (Chair)
12:40 – 13:05 Lung Cancer in Asia: Screening, and IPN Management
– Risk Factors
– Discuss Asia Screening Consensus recommendations
– IPN Management in Asia		 Dr. David Lam
13:05 – 13:20 Q & A (Poll)

Title Triple Therapy in COPD – Are They All The Same?
Details Date: 17 Nov 2023
Time: 17:00 – 17:50
Venue: Suntec Convention Center, Level 4, Sentosa Hall 404A
Synopsis The role of Triple Therapy in COPD management has become increasingly important. In the most recent GOLD update, it was recommended as Initial Therapy in Group E patients with blood eosinophil ≥ 300 cells/µL. Triple therapy has also been singled out as the only pharmacotherapy that can reduce the risk of mortality in patients with COPD.

In this talk, we will discuss the differences among the various triple therapies in COPD and how to personalise treatment based on latest evidence.
Objectives
  • Discuss latest updates to GOLD strategy, and the role of ICS in COPD management
  • Discuss current evidence behind Triple Therapy for COPD and the differences among options available
Faculty SpeakerProf. Song Yuanlin
Director
Department of Pulmonary and Critical Care Medicine
Zhongshan Hospital
Fudan University, China		 Prof. Song Yuanlin

Prof. Song Yuanlin is the Director of the Department of Pulmonary and Critical Care Medicine at Zhongshan Hospital, Fudan University. He also serves as a Standing Committee member in the Chinese Thoracic Society; Standing Committee member in APSR; President of the Shanghai Respiratory Society; Past Assembly Head of the Respiratory Infectious Disease (APSR) and is an Associate Editor for Respirology.
He has published over 200 papers in high impact journals including JAMA Internal Medicine, Lancet, JCI, Critical Care Med, Am J Respir Crit Care Med, Stem Cell, etc. and has a total h-index of 59. He also holds 20 approved patents and has co-authored 12 book chapters.
Schedule Time Description/Title
17:00 – 17:10 Hot Off the Press:
What’s New in GOLD Strategy?
17:10 – 17:30 Latest Evidence on Triple Therapies –
How Are They Different?
17:30 – 17:40 Selecting the Right Triple Therapy:
Patient Case Studies
17:40 – 17:50 Q & A (Poll)

Title Evidence-based approach for early antifibrotic treatment for Progressive Pulmonary Fibrosis
Details Date: Nov 17, 2023 (Friday)
Time: 12:30- 13:30
Venue: Suntec Convention Centre, Level 3, Room 332
Synopsis This event aims to address the knowledge gaps in early treatment for Progressive Pulmonary Fibrosis (PPF) and the importance of evidence-based approach for early antifibrotic treatment for PPF. Additionally, a case will be presented highlighting the regional challenge for early antifibrotic treatment for PPF and a panel discussion to share perspectives on how to apply an evidence-based approach for early antifibrotic treatment for patients’ optimal outcome.
Objectives · To understand clinical course of progressive pulmonary fibrosis (PPF) vs Idiopathic pulmonary fibrosis (IPF) and evidence-based approach for early antifibrotic treatment for PPF
· To understand perspectives on how to achieve best practice for patient’s optimal outcome
Faculty Prof. Martin Kolb, Canada

Prof. Martin Kolb is the Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Disease and the Director of the Division of Respirology, McMaster University, Hamilton, Ontario, Canada. His major research interests are fibrotic lung disease, with a particular interest in the role of growth factors and matrix abnormalities in disease progression. He leads activities in biomarker development for lung fibrosis, and is a Principal Investigator and steering committee member in numerous ILD clinical trials. Professor Kolb has authored over 280 peer-reviewed publications on different basic science and clinical topics with an H-Factor above 70. He was the Chief-Editor of the European Respiratory Journal (2018-2022) and currently is the journal’s Section Editor for Interstitial Lung Disease. He is also an editorial board member of several journals, including  American Journal of Respiratory and Critical Care Medicine and European Respiratory Review and Respirology.
Dr. Chai Gin Tsen, Singapore

Dr. Chai Gin Tsen is a senior consultant at department of respiratory and critical care medicine at Tan Tock Seng Hospital, Singapore. He is also a visiting consultant (Advisory and Teaching role) in the Department of Cardiothoracic Surgery, National Heart Centre Singapore and adjunct Lecturer, Lee Kong Chian School of Medicine, NanyangTechnological University.
Dr. Felicia Teo, Singapore

Dr. Felicia Teo is senior consultant at respiratory &intensive care medicine at the lung clinic, Mount Elizabeth Medical Center. She is also a visiting consultant at Division of Respiratory & Critical Care Medicine, University Medicine Cluster

National University Health System. She has special interest in Interstitial Lung Disease, Pulmonary Infections in the Immunocompromised, Pulmonary Immunology, Rare Lung Diseases and has written numerous publications on the topic.
Schedule  Time Description/Title
12:30 – 12:35 Welcome & Introduction Chair: Dr. Chai Gin Tsen
12:35 – 13:00 Clinical Course of PPF vs IPF & evidence-based approach for early antifibrotic treatment for PPF Prof. Martin Kolb
13:00 – 13:25 Discussion:
· Regional Challenge for early antifibrotic treatment for PPF (case study)
· How to achieve best practice for PPF patients		 Dr. Chai Gin Tsen (facilitator)

Prof. Felicia Teo (case presenter)

Prof. Martin Kolb
13:25 – 13:30 Summary & Conclusion Chair: Dr. Chai Gin Tsen

Title Advancing Respiratory Care: Strategies for Optimising Chronic Respiratory Treatment Outcomes
Details Date: Friday, 17 November 2023
Time: 12:30 – 13:30
Venue : Suntec Convention Center, Level 4 , Changi Hall 406D
Synopsis Data shows there is significant unmet need in Asthma management and despite new treatment options, patients continue to suffer from uncontrolled asthma, impacting their daily lives. The symposia plans to look at the latest data from single inhaler Triple Therapies and evaluate different treatment options for managing moderate to severe asthma: enabling the pulmonologist to identify appropriate asthma patients suitable for Triple Therapy earlier and optimising patient outcomes.
Objectives • To raise awareness on the unmet need in moderate to severe asthma management and look at the latest treatment options and data.
• Discuss identifying the appropriate Asthma patients suitable for Triple Therapy earlier and optimising patient outcomes in line with international recommendations.
Faculty Prof. John Blakey, Australia

Prof John Blakey is a respiratory physician who undertook a PhD and subspecialty training in airways disease in the UK, where he co-chaired the largest severe asthma network and contributed to national level guidelines and audit in COPD. Since moving to Australia, he has been the lead for asthma and airways disease at Sir Charles Gairdner Hospital, Perth and medical advisor for Asthma Australia and Asthma WA. John continues to be research-active though the Institute for Respiratory Health and Curtin University, with work supported by major funders such as NHMRC and industry. He also has a track record of delivering service improvement, recognised at national awards, and is active with the Thoracic Society of Australia and New Zealand.
Prof. Philip Eng, Singapore

Prof Philip Eng is Senior Consultant Respiratory & ICU Physician at Mt Elizabeth Medical Centre and Associate Professor of Medicine at the National University of Singapore. Previously he was Head, Dept of Respiratory & Critical Care Medicine at the Singapore General Hospital for 10 years, and past President of the Singapore Thoracic Society and past Regent of the American College of Chest Physicians. He was Congress President of the 4th Asia Pacific Congress on Bronchology (1997) and the 15th World Congress on Tobacco or Health (2008). He is currently on the Exco of the Asia Pacific Society of Respirology as Chairman of Education Committee. He was also past Head of the Clinical Respiratory Medicine Assembly and Bronchoscopy Assembly of the APSR. He has published more than 120 articles in peer reviewed international journals. His interests include ICU, Chest Radiology, Lung Cancer and Interventional Bronchoscopy.
Schedule  Time Description/Title
12:30 – 12:35 Welcome and introduction Prof. Philip Eng
12:35 – 13:10 Advancement in Asthma management: identify and improve patient outcomes using single inhaler triple therapies in-line with international recommendations Prof. John Blakey
13:10 – 13:25 Q&A panel discussion All faculty
13:25 – 13:30 Summary and close  Prof. Philip Eng

Title Clinical Remission in Severe Asthma –is it possible to achieve with Biologics?
Details Date: 17 Nov 2023
Time: 17:00 – 18:00
Venue: Suntec Convention Center, Level 4 , Changi Hall 406D
Synopsis Clinical remission is a multi-component treatment goal that can offer patients to reach new levels of treatment control and freedom from steroid use. There is growing evidence that long-term add on therapies as biologics can help achieve this goal in in a proportion of patients. Clinical remission is essential to change the landscape of severe asthma management.
Objectives • To discuss the ongoing drive towards clinical remission as an achievable treatment goal in severe asthma through timely biologic intervention
• To get a HCP and patient perspective on setting CR as a treatment goal
Faculty Speaker A/Prof. Mariko Koh

A/Prof. Mariko Koh is a senior consultant in the Department of Respiratory and Critical Care Medicine, Singapore General Hospital (SGH). Her clinical and research interests are in Severe Asthma and Airway diseases. She established the multidisciplinary Singapore General Hospital Severe Asthma Clinic in 2011 and leads a team of doctors, nurses, pharmacists, and other allied health professionals in the SGH Airway Diseases Program. She is also active in various Ministry of Health and Asthma committees, has academic collaborations from various institutions and universities, has >100 publications and sits in editorial boards of a few journals.
Chair Prof. Phil Bardin

Prof. Phil Bardin is Professor of Respiratory Medicine in the Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia. Since 2008 he has been Director, Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne.
He is recognised for investigation of obstructive lung diseases (particularly virus-asthma-COPD exacerbations) and has conducted extensive research of new asthma and COPD therapies. Recently research has also focused on vocal cord dysfunction in obstructive lung diseases. He is a recipient of ongoing Australian NH&MRC funding, has chaired the Australian NH&MRC Grant Review Panel (Respiratory & Sleep Medicine) and served on the Australian NH&MRC Academy. His professional activities reflect a career-long commitment to research and medical education, particularly in the areas of asthma and COPD.
Currently he is co-Editor-in-Chief of Respirology, official journal of the TSANZ and APSR
Schedule  Time Description/Title Faculty
17:00 – 17:35 Clinical remission with biologics – evidence and experience  A/Prof. Mariko Koh
17:35 – 17:55 Panel discussion and Q & A  All faculty
17:55 – 18:00 Closing remarks  Prof. Phil Bardin

Title Addressing Respiratory Infections: The Power of mRNA Vaccines & The Burden of RSV
Details Date: Friday 17th November
Time: 12:30 – 13:30
Venue: Suntec Convention Center, Level 4, Esplanade Hall 406CX
Synopsis Lower respiratory tract infections were the fifth most common cause of death in 2019 in middle-to-high income countries and the second leading cause of death in low income countries.1 Since the onset of the pandemic, the impact of respiratory infections on mortality rates has significantly escalated.

In this symposium, our expert speakers will delve into the latest advancements in mRNA vaccine technology, discussing its application in combating respiratory infection, with a focus on COVID-19 and updated variant matched vaccines.

The second part of this symposium will shed light on RSV, a common yet underestimated respiratory virus. We will explore the hidden burden of RSV, its epidemiology and impact on higher risk individuals such as older adults and individuals with comorbidities including lung and heart conditions, highlighting the need for increased awareness and improved management strategies.
Faculty Adj Assoc Prof. See Kay Choong,
MBBS, MRCP, FRCP Edin, MPH, MHPE, EDIC, FCCPAdj Assoc Prof Kay Choong See is currently a Senior Consultant Respiratory Physician and Intensivist at the National University Hospital, Singapore. He is also the Associate Designated Institutional Official for the National University Health System Residency Program.Adj Assoc Prof See completed Advanced Specialty Training in both Respiratory Medicine and Intensive Care Medicine in Singapore, a Master of Public Health at the Harvard School of Public Health, and a Master of Health Professions Education at Maastricht University.His special interests include public health, medical education, and healthcare quality improvement.
Dr. Claire Borg,
BSc (Hons), PhDDr Borg is Associate Director of Scientific Leadership, Asia Pacific and Latin America, at Moderna. Claire joined the vaccines industry 14 years ago and has worked across a broad portfolio covering pediatric and adult vaccines.Prior to her move to industry, Dr Borg was a research academic, completing her PhD in the Department of Medicine at Monash University where she investigated the genetic etiology of male infertility.
Prof. Grant Waterer,
MBBS, PhD, MBA, FRACP, FCCPDr. Grant Waterer, a Clinical Professor of Medicine at the University of Western Australia, holds adjunct professorships at Northwestern University, Curtin University, and Edith Cowan University. He serves as the Executive Director of Medical Services for East Metropolitan Health Service and Senior Medical Advisor for Medical Research and Innovation at the Western Australian Department of Health.His research focuses on pulmonary infections, particularly pneumonia and non-tuberculous mycobacterial disease, as well as bronchiectasis and COPD. Dr. Waterer has over 260 peer-reviewed publications and has presented at over 80 international conferences. He has held editorial positions at numerous journals and has contributed to key pneumonia guidelines. He also serves on the board of the Lions Eye Institute of Western Australia and various international advisory boards.
Schedule Time Description/Title Faculty
12:40 – 12:45 Welcome and Introduction Adj Assoc Prof. See Kay Choong
12:45 – 13:00 Tackling respiratory infection with mRNA vaccines

· Moderna’s mRNA platform and COVID-19 vaccine development
· Importance of variant-matched vaccines, focus on XBB1.5
· Moderna’s respiratory vaccines pipeline

 Dr. Claire Borg
13:00 – 13:20 Uncovering the hidden burden of RSV

· RSV epidemiology and disease burden in older adults
· Comparison of the burden of influenza and RSV
· Impact in people with comorbidities
· Unmet needs in diagnosis and prevention

 Prof. Grant Waterer
13:20 – 13:30 Q+A
Close		 Adj Assoc Prof. See Kay Choong
Dr. Claire Borg
Prof. Grant Waterer

Title Treatment & diagnosis in the AMR era: Pneumonia
Details Date: Friday, 17 November 2023
Time: 12:30–13:30
Venue: Suntec Convention Center, Level 4, Orchard Hall 405B
Synopsis Multidrug-resistant (MDR) Gram-negative bacterial (GNB) infections continue to pose a serious threat to critically ill patients in intensive care units (ICU). This event will explore and address the challenges faced in the management of MDR GNB infections in the ICU, covering pertinent topics such as novel treatment approaches, decision-making, and rapid diagnostics.
Objectives • Explore the current epidemiology of carbapenem-resistant Enterobacterales (CRE)
• Discuss the diagnosis and current treatment options of extended-spectrum beta-lactamases (ESBLs)
• Explore and address the challenges encountered in the ICU in the management of MDR GNB infections
• Discuss the role of rapid diagnostics in the optimization of treatment strategies for MDR GNB infections
Faculty Dr. Kenneth Chan

Dr Kenneth Chan is a specialist in respiratory medicine at the Respiratory Medical Associates in Singapore. His special interests include bronchoscopy, smoking cessation, and intensive care medicine. He is also a visiting consultant to Singapore General Hospital and an Adjunct Assistant Professor at the Duke-NUS Graduate Medical School. Dr Chan received his MBBS and MMed in Internal Medicine from the National University of Singapore. He is a member of the Royal College of Physicians, UK, a Fellow of the Academy of Medicine, Singapore, and a Fellow of the American College of Chest Physicians.
Prof. Antoni Torres

Professor Antoni Torres is Chief and Senior Consultant of the Respiratory and Intensive Care Unit at the Hospital Clinic of Barcelona, and Professor of Medicine at the University of Barcelona, Spain. In 2019, Prof Torres was appointed as Chairman of the Spanish Society of Pulmonology, where he developed national guidelines for hospital-acquired pneumonia. To date, Prof Torres has published 676 original articles and 195 book chapters, with an H-index of 116. In addition, he has participated in 68 publicly funded research projects and 16 European Union projects. He is currently Associate Editor of the European Respiratory Journal, European Respiratory Review, Thorax, Intensive Care Med and BMC Infectious Diseases. Prof Torres obtained his degree in Medicine from the University of Barcelona, before completing his residency in Pneumology at the Hospital Clinic of Barcelona.
Schedule Time Topic Speaker/Chairperson
12:30 – 12:35 Welcome & Introduction Dr. Kenneth Chan
12:35 – 12:55 Treatment & Diagnosis in the AMR Era: Pneumonia, Lung Disease Prof. Antoni Torres
12:55 – 13:10 Patient Case Study: Challenging MDRO Cases Prof. Antoni Torres
13:10 – 13:15 Q&A Prof. Antoni Torres
Dr. Kenneth Chan
13:15 – 13:30 Summary & Closing Dr. Kenneth Chan

Title The future of COVID-19 management: a spotlight on respirology
Details Date: Friday, 17th November 2023
Time: 17:00 – 18:00
Venue: Suntec Convention Center, Level 4 , Orchard Hall 405B
Synopsis Patients with pre-existing respiratory conditions such as asthma and COPD are at increased risk of progression to severe COVID-19.1,2 In this meeting the faculty will discuss the importance of identifying risk factors for severe COVID-19 that are common in Asia, and the need for early diagnosis and intervention, including the important role that respiratory specialists play. They will also highlight practical guidance on co-medication management with a focus on how and when to administer treatment, while discussing the latest COVID-19 eligibility and treatment guidelines with the support of clinical case studies and real-world data.

1. Aveyard P, et al. Lancet Respir Med 2021;9:909–23; 2. CDC. People with Certain Medical Conditions: www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions-people-with-medical-conditions.html (Accessed October 2023).
Objectives • Explore the impact of COVID-19 infection on patients with existing respiratory conditions to emphasise the need for early diagnosis and treatment in these patient types
• Review the latest updates of the eligibility and treatment guidelines for COVID-19, with a focus on patients with existing respiratory conditions
• Provide regional perspectives on the management of COVID-19 with a focus on patients with existing respiratory conditions
• Discuss the current clinical data and real-world evidence supporting nirmatrelvir/ritonavir as a treatment option for COVID-19
Faculty Dr Chan Kwok Wai Adrian, Singapore (Chair)

Consultant Respiratory Physician and Intensivist, Mount Elizabeth Novena Hospital, Singapore
Dr Yang Kuang-Yao, Taiwan

Professor, Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Schedule Time Topic Speaker/Chairperson
17:00–17:05 Welcome and introduction Dr Chan Kwok Wai Adrian, Singapore
17:05–17:35 COVID-19 management: demonstrating antiviral benefit with clinical trials and real-world evidence Dr Yang Kuang-Yao, Taiwan
17:35–17:45 Ask me anything – managing COVID-19: Q&A All faculty
17:45 Closing remarks Dr Chan Kwok Wai Adrian, Singapore

18 November 2023 Saturday

Title Is Clinical Remission the Future of Severe Asthma?
Details Date: Saturday, 18 November 2023
Time: 12:30 – 13:15
Venue: Suntec Convention Center, Level 4 ,Sentosa Hall 404A
Synopsis Clinical remission in severe asthma represents a breath of relief for patients. It signifies a state of symptom-free living, where asthma’s grip loosens, enabling individuals to lead fuller, healthier lives. Understanding the pathways to achieve and maintain this remission is key to transforming the landscape of severe asthma management.
Objectives Shed light on current different clinical remission criteria used across the world and new data on remission for biologics.
Faculty Prof. Ian Pavord, UK

Ian Pavord is a Professor of Respiratory Medicine at the University of Oxford and an Honorary Consultant Physician at the Oxford University Hospitals. He is a member of congregation at the University of Oxford and a Professorial Fellow of St Edmund Hall. He was a Consultant Physician from 1995 and Honorary Professor of Medicine from 2005 to 2013 at the Institute for Lung Health, Glenfield Hospital, University Hospitals of Leicester NHS Trust. He was elected an NIHR Senior Investigator in 2011& 2014, an inaugural Fellow of the European Respiratory Society in 2014 and a Fellow of the Academy of Medical Science in 2015.
Schedule  Time Description/Title
12:30 – 12:45 Clinical remission in Severe Asthma: is it possible?
12:45 – 12:55 Current Evidence on Clinical Remission
12:55 – 13:05 How to identify the right patients aiming remission in a resource-constrained set
13:05 – 13:15 Q&A

Title COPD: A CardiOPulmonary Disease?
Details Date: Saturday, 18 November 2023
Time: 17:00 – 17:50
Venue : Suntec Convention Center, Level 4 , Sentosa Hall 404A
Synopsis Up to 40% of patients with chronic obstructive pulmonary disease (COPD) die of cardiovascular causes. In a Southeast Asian study of Chinese patients with COPD, two-year mortality was the highest at 42.6% in the cluster with co-existing cardiovascular disease (CVD). As we start to uncover more about the mechanisms behind COPD-driven cardiopulmonary risk, what does it mean for clinical practice moving forward?
Objectives This symposium aims to:
· Discuss the relationship between COPD and CVD from both a pulmonologist’s and cardiologist’s perspective
· Discuss approaches to reduce cardiopulmonary risk in patients with COPD, drawing from lessons learnt in cardiology and the latest evidence in COPD treatment modalities
· Explore new ways to optimise COPD management through a multi-disciplinary team approach
Faculty Prof. Wisia Wedzicha Prof Wisia Wedzicha

Prof Wisia Wedzicha is Professor of Respiratory Medicine, Head of the Respiratory Division at the National Heart and Lung Institute, Imperial College, Consul at Imperial College and Honorary Consultant at Royal Brompton and Harefield Hospitals. She qualified from Somerville College, Oxford University and St Bartholomew’s Hospital Medical College. She was elected as Fellow of the Academy of Medical Sciences (FMedSci) and is a fellow both of the American Thoracic Society (ATSF) and European Respiratory Society (FERS). She received the Helmholtz International Fellow Award in 2014.

Professor Wedzicha has a major interest in the causes, mechanisms, impact and prevention of chronic obstructive pulmonary disease (COPD) exacerbations, and in the role of bacterial and viral infection in COPD exacerbations. She directs an active research group specialising in COPD exacerbations and has published extensively on this topic. She also directs the British Lung Foundation Early COPD Cohort.

Professor Wedzicha was Editor-in-Chief of Thorax from 2002 to 2010 and till March 2022 the Editor in Chief for the American Journal of Respiratory and Critical Care Medicine. She was the Lancet Ombudsman till 2014, Publications Director for the European Respiratory Society (ERS) and has also previously been ERS Guidelines Director. She is a member of the GOLD Scientific Committee.
Dr. Sheldon Lee Dr Sheldon Lee

Dr Sheldon Lee graduated from the National University of Singapore (NUS), Yong Loo Lin School of Medicine in 2003. He then went on to obtain his MRCP(UK) in 2010 and registered as a cardiologist with SMC since 2013. Dr Lee received his fellowship training in advanced heart failure management at St Vincent’s Hospital, New South Wales, Australia from 2015 to 2016 and completed another fellowship in cardiac magnetic resonance imaging in the Royal Brompton Hospital, London, U.K in 2016. Upon his return, he served in the Changi General Hospital as consultant and Director of the Heart Failure program till 2023. He is currently an accredited specialist cardiologist at several leading private hospitals in Singapore.

Dr. Xu Huiying

 Dr Xu Huiying

Dr Xu Huiying is a Senior Consultant respiratory physician in Tan Tock Seng Hospital, Singapore. She received her fellowship training in advanced COPD in the Royal Brompton Hospital, London. During her training in the UK, she was appointed as a research fellow in the National Heart and Lung Institute, Imperial College London. Apart from her clinical interest in COPD, Dr Xu is also active in medical education and is the Programme Director for the National Healthcare Group (NHG) Respiratory Medicine Residency Programme. She was awarded the NHG Teaching Award for Senior Doctors in 2022.
Schedule Time Description/Title Speaker
17:00 – 17:03 Welcome & Introduction Dr. Xu Huiying
17:03 – 17:18 COPD and CVD: Dangerous Liaisons
A cardiologist’s perspective Dr. Sheldon Lee
A pulmonologist’s perspective Prof. Wisia Wedzicha
17:18 – 17:33 Reducing Cardiopulmonary Risk in Patients with COPD
Prioritising Mortality Reduction as a Treatment Goal: Reflections from a Cardiologist Dr. Sheldon Lee
Rethinking COPD Management:
Treat-to-Prevent, or Treat-to-Failure?		 Prof. Wisia Wedzicha
17:33 – 17:48 Panel Discussion:
Expanding our view of COPD to a CardiOPulmonary Disease		 Prof. Wisia Wedzicha
Dr. Sheldon Lee
Dr. Xu Huiying (Moderator)
17:48 – 17:50 Summary & Closing Dr. Xu Huiying

Title The Future in Pulmonary Fibrosis – A Potential Novel Strategy?
Details Date: Saturday, 18 November 2023
Time: 12:30- 13:30
Venue: Suntec Convention Centre, Level 3, Room 332
Synopsis This event will explore the future of Pulmonary Fibrosis by examining global guidelines and discussion covering clinical trials in pulmonary fibrosis, available therapies, and the latest developments in Interstitial Lung Disease (ILD). Attendees will gain a deeper understanding of the current state and potential novel strategies in Pulmonary Fibrosis.
Objectives  To explore the future of Pulmonary Fibrosis by examining global guidelines and latest developments
Faculty Prof. Martin Kolb, Canada

Prof. Martin Kolb is the Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Disease and the Director of the Division of Respirology, McMaster University, Hamilton, Ontario, Canada. His major research interests are fibrotic lung disease, with a particular interest in the role of growth factors and matrix abnormalities in disease progression. He leads activities in biomarker development for lung fibrosis, and is a Principal Investigator and steering committee member in numerous ILD clinical trials. Professor Kolb has authored over 280 peer-reviewed publications on different basic science and clinical topics with an H-Factor above 70. He was the Chief-Editor of the European Respiratory Journal (2018-2022) and currently is the journal’s Section Editor for Interstitial Lung Disease. He is also an editorial board member of several journals, including  American Journal of Respiratory and Critical Care Medicine and European Respiratory Review and Respirology.
Dr. Syazatul Syakirin, Malaysia

Dr Syazatul Syakirin is a Respiratory Physician at Institut Perubatan Respiratori, HKL Kuala Lumpur, Malaysia. She has special interest in interstitial lung diseases and has written numerous publications on the topic.
Schedule  Time Description/Title
12:30 – 12:35 Welcome & Introduction Chair: Dr. Syazatul Syakirin
12:35 – 13:05 The Future in Pulmonary Fibrosis – A Potential Novel Strategy? Prof. Martin Kolb
13:05 – 13:25 Q & A Prof. Martin Kolb
Dr. Syazatul Syakirin
13:25 – 13:30 Summary & Conclusion Chair: Dr. Syazatul Syakirin

Title Bringing to light infectious disease threats for chronic respiratory patients
Details Date: Saturday 18 November 2023
Time: 12:30-13:30
Venue: Suntec Convention Hall, Level 4 , Changi Hall 406D
Synopsis Data shows that risk of pertussis, RSV and shingles is increased in COPD and asthma patients and that pertussis and RSV also play a role in COPD exacerbations.
The symposium plans to address an unmet medical need: enable the pulmonologists to understand the risk/impact of herpes zoster and pertussis in
patients with COPD and asthma and the need for prevention through vaccination.
For both diseases, recent recommendations and guidelines updates for prevention in patients with COPD will be discussed.
Objectives To raise awareness on the increased risk of infectious diseases (RV, pertussis and herpes zoster) for patients suffering of chronic respiratory diseases like asthma and COPD. Discuss the link between infectious diseases and exacerbations and the potential to prevent them by vaccination.
Faculty A/Prof. Mariko Koh

A/Prof. Mariko Koh is a senior consultant in the Department of Respiratory and Critical Care Medicine, Singapore General Hospital (SGH). Her clinical and research interests are in Severe Asthma and Airway diseases. She established the multidisciplinary Singapore General Hospital Severe Asthma Clinic in 2011 and leads a team of doctors, nurses, pharmacists, and other allied health professionals in the SGH Airway Diseases Program. She is also active in various Ministry of Health and Asthma committees, has academic collaborations from various institutions and universities, has >100 publications and sits in editorial boards of a few journals.
Dr. Susanthy Djajalaksana

Dr. Susanthy Djajalaksana – Pulmonology and Respiratory Medicine  – Saiful Anwar General Hospital East Java – Universitas Brawijaya Malang Indonesia – Indonesia

Dr Susanthy hold Pulmonology and Respiratory Medicine on Year 2005 and reached her Doctorate degree on Year 2012 from Brawijaya University.

Dr Susanthy is currently serve as Head of School of Pulmonology and Respiratory Medicine Department Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia from Year 2018 until present.

She practice as Respiratory Medical Specialist at Saiful Anwar General Hospital, Hermina Hospital, and Lavallete Hospital at Malang, Indonesia.

She’s actively involved in some research focus. Recently she was involved as investigator on clinical trial titled “The Predictors of high titer of anti SARS-CoV-2 antibody of convalescent plasma donors”, which was funded by Ministry of National Research and Innovation Agency of the Republic Indonesia and Indonesia Endowment Fund for Education Ministry of Finance of the Republic Indonesia.

She hold some patents and proprietary rights, such as Book of Senam Asma on Year 2020 and Computer Program of Memori Asma on Year 2021.
Dr. Jim Teo Yeow Kwan

Dr. Jim Teo Yeow Kwan – Internal medicine, respiratory medicine and intensive care medicine – Private practice – Singapore

Dr Jim Teo is accredited in internal medicine, respiratory medicine and intensive care medicine by Ministry of Health. He did one-year intensive care medicine fellowship in Australia. He holds both the European Diplomas in Adult Respiratory Medicine and Intensive Care Medicine. His special interests include interstitial lung disease, chronic lung infection, tuberculosis and non-invasive ventilation.
Schedule  Time Description/Title Faculty
12:30 – 12:33 Welcome and introduction  A/Prof. Mariko Koh (Chair)
12:33 – 12:47 RSV and other infectious disease, what is the risk for your COPD and asthma patients? A/Prof. Mariko Koh
12:47 – 13:00 The shadow of pertussis in chronic respiratory disease Dr. Susanthy Djajalaksana
13:00 – 13:13 Shining a spotlight on shingles in chronic respiratory disease  Dr. Jim Teo Yeow Kwan
13:13 – 13:18 Panel discussion and Q&A session; Evolving prevention strategies in the management of respiratory patients A/Prof. Mariko Koh
13:18 – 13:30 Panel discussion and Q&A session; Summary and close  All – Moderated by A/Prof. Mariko Koh

Title Spotlight on COVID-19: A look at the latest insights and future trends
Details Date: Saturday, 18 November 2023
Time: 12:30 – 13:30
Venue: Suntec Convention Center, Level 4, Orchard Hall 405B
Synopsis Coronavirus disease 2019 (COVID-19) is continuing to spread throughout the globe, impacting human health in unprecedented ways – our understanding of the disease and our needs are rapidly evolving in response to emerging challenges and new insights.
Objectives · Describe the clinical features and clinical course of acute and post-acute sequelae associated with COVID-19.
· Discuss the risk and protective factors for severe and long COVID and evidence for the role of COVID-19 vaccination in their prevention.
· Review the epidemiology and characteristics of emerging SARS-CoV-2 variants of concern and practical strategies for optimizing COVID-19 control.
· Review the evolution of the vaccine development and approval paradigms and its impact on COVID-19 preparedness and response.
Faculty A/Prof. Philip Eng, Singapore

Dr Philip Eng is Senior Consultant Respiratory Physician at Philip Eng Respiratory and Medical Clinic, Mount Elizabeth Medical Center, Singapore. In addition, he is Associate Professor of Medicine at the National University of Singapore and a Visiting Consultant at Singapore General Hospital, Singapore. Dr Eng has published more than 100 peer-reviewed articles and contributed to several books and book chapters. He has both organized and chaired conferences and delivered lectures in Singapore and internationally. Currently, Dr Eng is an Executive Committee Member of the Asia Pacific Society of Respirology (APSR).
Prof. Stephen Thomas, USA

Professor Stephen Thomas holds concurrent positions as Professor of Medicine and Microbiology & Immunology, Chief of the Division of Infectious Diseases, and Director of the Institute for Global Health and Translational Sciences at State University of New York, Upstate Medical University, NY, USA. Professor Thomas has dedicated his career to the prevention, control, and treatment of infectious diseases. To date, he has contributed to more than 120 original research articles and several book chapters and presented numerous abstracts at local and international conferences. Professor Thomas’ expertise is widely sought; he has been member of various national and international vaccine committees and advisory boards. In addition, he is a reviewer of various prestigious journals, such as Nature, New England Journal of Medicine, Science Translational Medicine, and Clinical Infectious Diseases.
Schedule Time Description/Title Faculty
12:30 – 12:35 Welcome and introductions A/Prof. Philip Eng (Singapore)
12:35 – 13:05 Spotlight on COVID-19: A look at the latest insights and future trends Prof. Stephen Thomas (USA)
13:05 – 13:25 Panel discussion / Q & A Faculty panel:
A/Prof. Philip Eng
Prof. Stephen Thomas
13:25 – 13:30 Meeting close A/Prof. Philip Eng

Title: Beyond Asthma Control in Severe Type 2 Asthma Management
Details: Date: Saturday, 18 November 2023
Time: 12:30 – 13:30
Venue: Suntec Convention Center, Level 4, Esplanade Hall 406CX
Synopsis: The concept of asthma has changed substantially in recent years. In the past, asthma was treated using a “one-size-fits-all” approach, where patients received the same medications regardless of their specific characteristics, and treatment primarily addressed symptoms without targeting the underlying inflammatory processes. However, the introduction of biomarkers and biologics has advanced the concept of precision medicine, which now considers the individual pheno-endotype of each patient. This novel approach might facilitate the achievement of asthma clinical remission, an ambitious goal that is still debated among academics about its definition and applicability. This talk reviews the new data on different biologics in severe asthma, the latest guidance in individualized management of severe type 2 asthma, and the concept of clinical remission.
Objectives: Update on the latest guidance in management of severe type 2 asthma and new data on biologics
Faculty: Assoc. Prof. Dr. Andrea Ban Yu-Lin

Dr Andrea Ban Yu-Lin  is a senior consultant phycisian and pulmonologist in Hospital Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM UKM), specializing in asthma and COPD. She is the current head of respiratory unit in the department of medicine.  She obtained her masters in medicine (MMED) from Universiti Kebangsaan Malaysia In 2006 and has since become a lecturer, physician and researcher in HCTM. She has conducted researches particularly in asthma, COPD and tuberculosis. She has published and presented in national and international congresses. She is a member of the Malaysian Thoracic Society (MTS) and Malaysian Association for Bronchology and Interventional Pulmonology (MABIP).  She was previously the chairperson of the national respiratory exit viva exam committee and  the chairperson for current national asthma clinical practice guidelines for adults. The  respiratory unit, department of medicine is an established centre for pulmonology training national fellows. The unit is  actively involved in teaching, running workshops.
Prof. Phillip Bardin, Melbourne, Australia

Phil Bardin is Professor of Respiratory Medicine in the Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia. Since 2008 he has been Director, Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne.

He is a practising clinician and is recognised for research of obstructive lung diseases (particularly asthma-COPD).  Has also conducted extensive research of new asthma and COPD therapies. Recently studies have included vocal cord dysfunction/inducible laryngeal obstruction (VCD/ILO), an important and common but neglected condition. His professional activities reflect a career-long commitment to research and medical education.

He is a recipient of ongoing Australian NH&MRC funding, has chaired the Australian NH&MRC Grant Review Panel (Respiratory & Sleep Medicine) and served on the Australian NH&MRC Academy. Currently he is co-Editor-in-Chief of Respirology, official journal of the TSANZ and APSR.
Schedule: Time Description
12:30 – 12:35 Opening A/Prof. Andrea Ban
12:35 – 13:10 Beyond Asthma Control in Severe Type 2 Asthma Management Prof. Philip Bardin
13:10 – 13:25 Q&A All
13:25 – 13:30 Closing A/Prof. Andrea Ban

Title: Spotlight on RSV – A Hidden Epidemic in Older Adults
Details: Date: Saturday, 18 November 2023
Time: 12:30 – 13:30
Venue : Suntec Convention Centre, Level 3, Room 336
Synopsis: The prevalence of RSV is globally underestimated and underappreciated in older adults. This burden is particularly high for adults living with high-risk medical conditions, such as heart disease, COPD, asthma, and other conditions that affect overall health. The transmission of RSV through long-term care facilities or hospitals is a particular concern due to their fragile patient populations, highlighting a need for effective precautions and preventative measures.

This program aims to raise awareness, promote understanding, and stimulate discussion around epidemiology, clinical manifestations, diagnostic challenges, and current plans for RSV prevention for this vulnerable patient population.
Objectives: This symposium aims to:
– Raise awareness and educate HCPs about RSV disease burden and clinical management in older adults;
– Facilitate implementation of new preventive options at a national and regional level.
Program Director Brigham and Women’s Hospital / Harvard Medical School, United States Dr. Daniel Kuritzkes, MD

Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group.

He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves as an Associate Editor of the Journal of Infectious Diseases.

His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.
Local Chair National Centre for Infectious Diseases (NCID), Singapore A/Prof. Barnaby Edward Young, MB BChir, PhD

A/Prof. Barnaby Young is an infectious disease senior consultant at the National Centre for Infectious Diseases (NCID) and Tan Tock Seng Hospital (TTSH) and jointly appointed Associate Professor (Clinical Practice) at Lee Kong Chian School of Medicine. He is Head of the Singapore Infectious Disease Clinical Research Network (SCRN) at NCID and co-ordinates prospective observational studies and randomised controlled trials in collaboration with public hospitals and polyclinics in Singapore. He is also the database core lead in Programme for Research in Epidemic Preparedness and Response (PREPARE), Ministry of Health. His research interests are in respiratory viral infections including SARS-CoV-2 and influenza. In 2023 he received a Clinician Scientist Award (CSA) from the National Medical Research Council (NMRC) with the aim of conducting a SARS-CoV-2 Controlled Human Infection study in Singapore.
Speaker National University Hospital, Singapore Dr. Jyoti Somani, MD

Dr. Somani is from the U.S. and has been living in Singapore since November 2014. She graduated from the University of Cincinnati medical school in 1991 and attended the University of Chicago Hospitals for her Internal Medicine Residency and the first year of her Infectious Disease Fellowship. She completed her ID fellowship at Emory University. Dr. Somani was in the US Indian Health Service (1998-2000), then became an Assistant Professor of Infectious Disease at Emory University (2000-2004). She started the Transplant ID Fellowship Elective, and was the ID Occupational Health Consultant for Yerkes Primate Centre. From 2004-2008, she worked on a HIV and Leadership Training Program for doctors in Chennai, India. She also spent time in private practice in Atlanta (2008-2012) and subsequently the Australian Embassy clinic and Siloam Hospitals in Jakarta (2012-2014).

Dr. Somani then joined the General Medicine Department at Khoo Teck Puat Hospital, Singapore in 2014. In late 2018, she moved to NUHS as a Senior Consultant for the Division of Infectious Diseases and as the Director of the ASP program. She is also the Director of the NUH Hospital Epidemiology Unit and Chair of the Infection Control Committee.  She has been actively involved in the COVID response for NUH, and remains passionate about the rational use of antibiotics. Her clinical interests include transplant related infectious diseases.
Speaker Singapore General Hospital, Singapore Dr. Ian Wee Liang En, MBBS(Hons), MCRP, MPH

Ian is a Consultant with the Department of Infectious Diseases, Singapore General Hospital. He also holds a Clinical Assistant Professor appointment at the Duke-NUS Graduate Medical School, Singapore, and concurrent appointments at the National Centre for Infectious Diseases (NCID) and National Public Health and Epidemiology Unit (NPHEU). His research interest relates to infectious diseases, including infections in immunocompromised hosts; infection prevention and control; and public health. He has published over 100 papers in peer-reviewed journals, including Clinical Infectious Diseases; Clinical Microbiology and Infection; JAMA Pediatrics; Infection Control and Hospital Epidemiology; and Journal of Hospital Infection. His current work is mainly focused on COVID-19 related research and epidemiology.
Schedule Time Description/Title Speaker
12:30 – 12:35 Welcome and Opening by Symposium Chair A/Prof. Barnaby Edward Young, MB BChir, PhD
12:35 – 12:50 RSV Epidemiology in Older Adults, and Implication for Chronic Respiratory Diseases Dr. Ian Wee Liang En, MBBS(Hons), MCRP, MPH
12:50 – 13:05 RSV Prevention – Review of Clinical Trials in the Elderly Dr. Jyoti Somani, MD
13:05 – 13:20 Discussion: RSV, Influenza and COVID Diagnostic and Vaccination – How to Put Them Together? Dr. Jyoti Somani, MD

Dr. Ian Wee Liang En, MBBS(Hons), MCRP, MPH

A/Prof. Barnaby Edward Young, MB BChir, PhD
13:20 Closure of the Symposium A/Prof. Barnaby Edward Young, MB BChir, PhD

The Spotlight on RSV – A Hidden Epidemic in Older Adults | Satellite Symposium at APSR 2023 is supported by an independent educational grant from Moderna. Moderna was not involved in the development of content or selection of faculty for this educational activity.

The opinions expressed within the Sponsored Satellite Symposia are solely the speakers’ and do not reflect the opinions and beliefs of APSR.